Splash Beverage expands CannEpil license to veterinary therapeutics in 8-K amendment

Splash Beverage Group amended a Form 8-K to reflect an expanded exclusive global CannEpil license covering veterinary therapeutics.

Added rights cover worldwide development, manufacturing, commercialization, marketing, distribution for veterinary diseases, creating a second FDA-regulated program.

Initial veterinary focus targets companion-animal oncology, chronic pain; plans FDA CVM pathways including INAD, Conditional Approval.

The amendment sets a 10% royalty on net revenues from veterinary CannEpil applications payable to Argent BioPharma.

A strategic joint venture under finalization with a cannabinoid pharmaceutical partner is expected to lead veterinary development.